Literature DB >> 8800643

Functional analysis of the human pro-opiomelanocortin promoter in the small cell lung carcinoma cell line DMS-79.

A Picon1, M Leblond-Francillard, M L Raffin-Sanson, F Lenne, X Bertagna, Y de Keyzer.   

Abstract

DMS-79 is a human cell line derived from a small cell lung carcinoma (SCLC), which expresses the pro-opiomelanocortin (POMC) gene. We took it as a model in which to study the mechanism of POMC gene expression in these tumors: precursor processing is altered and gene expression is essentially unresponsive to glucocorticoids. POMC gene structure appeared normal by Southern blot analysis, indicating that gene rearrangement was not responsible for its expression in DMS-79. Indeed, using transient expression of human POMC-luciferase fusion genes in DMS-79, we showed that (1) the normal human POMC promoter was functional in DMS-79, and (2) the same proximal promoter region (-417; + 21) produced the full transcriptional activity in DMS-79 and in the mouse pituitary cell line AtT-20. Progressive 5' deletion analysis revealed differences between AtT-20 and DMS-79: region (-611; -376) was active in AtT-20 and not in DMS-79, whereas region (-95; -161) was active in both cell lines and (-376; -417) was only active in DMS-79. The latter partially overlaps a motif homologous to the DE-2 rat element which confers the tissue-specific expression of POMC in AtT-20 cells; however, this motif had no effect in DMS-79. These data suggest that POMC gene transcription is achieved through a different set of transacting factors in DMS-79 and AtT-20. Altogether, our results provide evidence that DMS-79 is a valid model of tumors responsible for the ectopic ACTH syndrome and that the mechanism of POMC gene expression in these SCLC cells is different from that in pituitary cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8800643     DOI: 10.1677/jme.0.0150187

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  4 in total

1.  E2F1-mediated human POMC expression in ectopic Cushing's syndrome.

Authors:  Takako Araki; Ning-Ai Liu; Yukiko Tone; Daniel Cuevas-Ramos; Roy Heltsley; Masahide Tone; Shlomo Melmed
Journal:  Endocr Relat Cancer       Date:  2016-10-07       Impact factor: 5.678

2.  Aberrant Nuclear Translocation of E2F1 and Its Association in Cushing's Disease.

Authors:  Takako Araki; Justin Wang; Ryan Lawrence; Yasuhiko Kawakami
Journal:  Endocrinology       Date:  2022-08-01       Impact factor: 5.051

Review 3.  Molecular Derangements and the Diagnosis of ACTH-Dependent Cushing's Syndrome.

Authors:  Lynnette K Nieman
Journal:  Endocr Rev       Date:  2022-09-26       Impact factor: 25.261

4.  The pituitary V3 vasopressin receptor and the corticotroph phenotype in ectopic ACTH syndrome.

Authors:  Y de Keyzer; F Lenne; C Auzan; S Jégou; P René; H Vaudry; J M Kuhn; J P Luton; E Clauser; X Bertagna
Journal:  J Clin Invest       Date:  1996-03-01       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.